Slaughter and May and Freshfields Bruckhaus Deringer have landed pivotal roles on a $13bn deal which sees GlaxoSmithKline (GSK) acquire the remaining 36.5% stake in its consumer healthcare joint venture with fellow pharma giant Novartis.
Slaughters is advising GSK with a team comprising corporate partners Simon Nicholls and David Johnson, alongside tax specialist Dominic Robertson, competition partner Bertrand Louveaux, and finance partners Guy O’Keefe and Oliver Storey. Meanwhile Freshfields is advising Novartis, fielding a team led by corporate partners Julian Long and Jennifer Bethlehem, accompanied by tax partner Paul Davison and antitrust partner Rod Carlton. The in-house legal team at GSK was led by senior vice president and head of legal corporate functions Chip Cale, and associate general counsel Antony Braithwaite.
Subscriber Access
You must be logged in to view full premium content.
